Clinical Trials in New York

Showing 7961-7980 of 22,668 trials

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

NCT01894672

The purpose of this phase II study is to find out if an investigational drug called LGX818 can stop the melanoma from growing.

Melanoma

Memorial Sloan Kettering Cancer Center7 participantsStarted Jul 2013

Basking Ridge, New Jersey, United States • Commack, New York, United States • New York, New York, United States +2 more locations

COMPLETEDPhase 1< 1 mile

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

NCT01798004

This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come back or spread. Giving chemotherapy to the entire body before a stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy or radiation therapy is given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy.

GanglioneuroblastomaStage 1 NeuroblastomaStage 2 Neuroblastoma+5 more

Children's Oncology Group150 participantsStarted Apr 2013

Birmingham, Alabama, United States • Downey, California, United States • Duarte, California, United States +120 more locations

BRAF Inhibitor, LGX818, Utilizing a Pulsatile Schedule in Patients With Stage IV or Unresectable Stage III Melanoma Characterized by a BRAFV600 Mutation

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Find Trials by Condition in New York

Belimumab Assessment of Safety in SLE

Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Feasibility Study on LITT for Medical Refractory Epilepsy

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

A Study of the Safety, Efficacy, and Biomarker Response of BMS-986165 in Participants With Moderate to Severe Ulcerative Colitis

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

Injections of Autologous PRP in Women With Primary Ovarian Insufficiency

Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia

Performance of WOUNDCHEK Bacterial Status

Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis

Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence

Impact of Microvascular Inflammation on Kidney Allograft Outcome